with a molecular mass of9 13.6 Da (Fig. 1) . In solution, sirolimus forms two conformational trans-, cis-isomers with a ratio of 4:1
due to hindered rotation around the pipecolic acid amide bond [3, 4] . Because of its triene structure, sirolimus has ultraviolet (UV) absorption maxima at 288, 276, and 266 nm.6 It is sparingly soluble in water, aliphatic hydrocarbons, and diethyl ether, whereas it is soluble in alcohols, halogenated hydrocarbons, and dimethyl sulfoxide [1, 5, 6] . Sirolimus is unstable in solution and degrades in plasma and low-and neutral-pH buffers at 37 #{176}C, with a half-life of <10 h [6, 7] . The structures of the degradation products have recently been characterized [8] .
Sirolimus is isolated from Si-reptomyces hygroscopicus [5, 9] and was originally developed as an antifungal [6, 10, Ii] and anticancer drug [6, 12] . Interest has also focused on its immunosuppressive activity [13] . Although it shares structural homology with the immunosuppressant tacrolimus and binds to the same intracellular binding protein in lymphocytes [14, 15] , it inhibits S6p70-kinase and therefore has a mechanism of immunosuppressive action distinct from that of tacrolimus [6, 16] . Sirolimus was found to prolong graft survival of different transplants in several species alone [6, [17] [18] [19] or in combination with other immunosuppressants [6, 20, 21] . In animal models its spectrum of toxic effects is different from that of cyclosporine or tacrolimus [6, 22] , comprising impairment of glucose homeostasis, stomach ulceration, weight loss, and thrombocytopenia [6, 17, 21] 21] . Sirolimus is under clinical investigation as an immunosuppressant after kidney transplantation. Sirolimus is metabolized by cytochrome P-450 3A to at least six metabolites [23, 24] . During incubation with human liver and small intestinal microsomes, sirolimus was hydroxylated and (or) demethylated, and the structure of 39-O-demethyl sirolimus was identified [24] . In bile of sirolimus-treated rats, >16 hydroxyl- [25] . HPLC assays have been described by several authors [24, [26] [27] [28] [29] . Most of these methods do not allow quantification of sirolimus metabolites [26] [27] [28] [29] and have other serious drawbacks: The method described by Sattler et al. [23] does not report any specifications, Napoli and Kahan [26] did not show that their method is able to quantify sirolimus in biological samples, and Yatscoff et al. [27] used demethyl sirolimus as internal standard, which is a potential sirolimus metabolite [24] and is present in blood of patients in concentrations equal to that of sirolimus (vide infra). The only HPLC/IJV assay described so far that is used for therapeutic drug monitoring of sirolimustreated patients is that described by Napoli and Kahan [29] . This assay does not allow quantification of metabolites and its sensitivity is limited to 2 gfL.
Because of its high immunosuppressive potency [6, 16, 30] ,a sensitive and specific assay for sirolimus and its metabolites that detects concentrations <1 g/L in tissue and biological fluids is required to evaluate its pharmacokinetics [6] .
MaterialsandMethods

INSTRUMENTS AND CHEMICALS
The following HPLCIESI-MS/MS system was used: A TSQ 700 mass spectrometer with electrospray fast-flow interface 
GENERATION AND PURIFICATION OF SIROLIMUS
METABOLITES
Sirolimus metabolites were generated as previously described [24] . Human liver microsomes were isolated by using standard centrifugation techniques [33] and the protein concentration The samples were centrifuged at 2SOOg for 2 mm and the supernatant drawn through glass extraction columns (Krannich, Gottingen, Germany) filled with C8 LiChroprep#{174}(Merck) of 25-40-jim particle size and previously washed with 3 mL of acetonitrile and 3 mL of sulfuric acid (pH 3). The samples were washed on the columns with 3 mL of methanol/sulfuric acid (pH 3, 50/50 by vol) and I mL of hexane and eluted with 1.5 mL of dichloromethane.
The dichloromethane eluates were pooled, evaporated at 40 #{176}C under a stream of nitrogen, and the residues dissolved in 1. extraction columns that had previously been primed with 2 mL of acetonitrile and 2 mL of sulfuric acid (pH 3). The pressure was adjusted to -5 mmHg. The extraction columns were washed with 2 mL of sulfuric acid (pH 3) and dried by drawing air through the columns for 2 mmn. Sirolimus, its metabolites, and the internal standard were eluted with 400 j.LL of acetonitrile/l % formic acid (90/10 by vol). Two hundred microliters were transferred into an HPLC microvial (Hewlett-Packard) and 100 1.L of the extract was injected into the HPLC system.
HPLC/ESI-MS
Sirolimus, its metabolites, and the internal standard were eluted isocratically from the analytical column with methanolll% formic acid (90/10 by vol) at a flow rate of 0.4 mL/min. To assess a potential interference with the sirolimus degradation products described by Wang et al. [8] , these were produced by using the method described [8] with a few modifications: One milligram of sirolimus was dissolved in 100 L of ethanol and incubated with 2 mL of 0.1 mol/L ammonium acetate (pH 8). The degradation products were separated on a 250 x 4 mm column filled with Hypersil C18 3-p.m material.
The flow rate was 0.7 mL/min and the same methanollO.05 mol/L ammonium acetate gradient as in the original method [8] was run. The UV-detector wavelength was set to 276 nm and fractions were manually collected. Two hundred microliters of the collected fractions were injected in the HPLC/MS system used for quantification of sirolimus and its metabolites.
Results
The reaction of sirolimus with acetic acid anhydride yielded two mono-and one diacetylated derivatives, which were isolated by semipreparative HPLC (Fig. 2) and identified by ESI-MS (Figs.  3 and 4) . Their structures were identified by ESI-MS/MS and CAD. In Fig. 3 [32] . These data could be applied as well to the analysis of the sodium adduct ions of sirolimus, its metabolites, and acetylation products by using ESI-MS/MS and CAD (Fig. 4) . Thus, the two isomeric monoacetyl 
28-O-acetymsirolimus.
Samples were prepared and analyzed as described in Materials and Methods. [34, 35] .They result in an m/z that, in contrast to demethyl sirolimus, which has also been used as an internal standard for an HPLC assay [27] ,can clearlybe distinguished from sirolimus and its metabolites.
Internal standards other than sirolimus derivatives such as tacrolimus or 13-estradiol-3-methyl ether [29] seem to be unsuitable since their stability during storage and their in-process stability may be different from that of sirolimus.
In the present study, identification of the structures of the acetylated sirolimus derivatives and the metabolites was based on the fast-atom bombardment results described by Kiplinger Because of their temperature-, concentration-, and hematocrit-dependent distribution in blood and their high affinity for the cellular components, blood is currently the generally accepted matrix for these immunosuppressants.
Since almost 95% of sirolimus in blood is found in erythrocytes, blood was recommended as the matrix for sirolimus as well [39] and therefore chosen as the matrix in this study. Several metabolites isolated after in vitro metabolism of sirolimus [24] and detected in bile of sirolimus-treated rats [25] were present in the blood of kidney transplant patients. In contrast to tacrolimus, which accounts for >80% of all tacrolimus derivatives in the blood of patients with stable liver function, sirolimus metabolites add up to higher concentrations than the unchanged drug. Sirolimus has a low oral bioavailability and a narrow therapeutic range in animal models [22] . Its elimination is very likely dependent on liver function, and drug-related side effects appear to be trough concentration related [22] . Furthermore, sirolimus is metabolized by enzymes of the cytochrome P-450 3A subfamily in the liver and small intestine [23, 24] , with the potential risk of numerous interactions at this level with drugs usually administered after organ transplantation [40] , resulting in modification of its trough blood concentrations. All this, as well as experience with tacrolimus and cyclosporine, requires the clarification of whether or not blood concentration-guided dose adjustments and regular therapeutic drug monitoring of sirolimus will be necessary.
HPLC/UV has been proposed as the method of choice [22] , mainly on the basis of animal studies [22, 41] ; the trough and peak blood concentrations in patients reported in our study are lower than those reported in animal studies [42] . Furthermore, the metabolites have generally lower concentrations [6, 42] , which allows even lower doses resulting in lower blood concentrations.
In 
